SYRE vs TVTX
Spyre Therapeutics, Inc. vs Travere Therapeutics, Inc. — AI-powered side-by-side comparison
SYRE
Spyre Therapeutics, Inc.
70
Buy
VS
TVTX
Travere Therapeutics, Inc.
67
Buy
| Metric | SYRE | TVTX |
|---|
| AI Score |
70
|
67
|
| Price |
$103.56
|
$62.07
|
| P/E Ratio |
-53.14×
|
-138.09×
|
| ROE |
-21.7%
|
-22.2%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
0.0%
|
94.4%
|
| Debt / Equity |
0.00×
|
25.16×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
54.6
|
64.5
|
| Beta |
3.026
|
1.042
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for SYRE versus TVTX.
SYRE leads by 3 points.
SYRE scores 70/100 (Buy) versus TVTX at 67/100 (Buy).
SYRE Committee View
83% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- ROE of only -24.3% -- cheap may mean cheap for a reason — Value
- MACD histogram negative -- bearish momentum — Technical
- Weekly RSI at 79 -- overbought on the larger timeframe too — Technical
TVTX Committee View
80% agreement
5 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — quarter-over-quarter growth rate is accelerating, not just positive. Risk Analyst remains cautious — bollinger bandwidth of 19.4% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Weekly RSI at 80 -- overbought on the larger timeframe too — Technical
- Bollinger bandwidth of 19.4% signals elevated volatility — Risk